Healthcare Services company Vimta Labs announced Q3FY26 results Revenue: Rs 986.33 million against Rs 899.23 million during Q3FY25, change 10%. PBT: Rs 249.87 million against Rs 239.16 million during Q3FY25, change 4%. PAT: Rs 175.86 million against Rs 175.16 million during Q3FY25, change 0%. EPS: 3.96 for Q3FY26. Result PDF
Healthcare Services company Vimta Labs announced Q2FY26 results Q2FY26 Financial Highlights: Total Income for Q2FY26 was at Rs 1,045 million EBITDA for Q2FY26 was Rs 369 million; EBITDA margin was at 35.3% PBT for Q2FY26 was at Rs 263 million Q2FY26 PAT was at Rs 199 million; PAT margin was at 19.1% Basic EPS in Q2FY26 was Rs 4.5 H1FY26 Financial Highlights: Total Income for H1FY26 was at Rs 2,038 million EBITDA for H1FY26 was Rs 723 million; EBITDA margin was at 35.5% PBT for H1FY26 was at Rs 515 million H1FY26 PAT was at Rs 388 million; PAT margin was at 19.0% Basic EPS in H1FY26 was Rs 8.7 Harita Vasireddi, Managing Director, Vimta Labs, said: "I am delighted to share that Vimta Labs had a successful quarter with highest ever revenue reported i.e. ~Rs 104 crore. This growth was a result of our Pharmaceutical research and testing services and Food testing services performing well, while experiencing stable performance from other services provided by us. We would like to mention that our company had a successful WHO audit for Clinical Research during the quarter, reflecting our commitment to maintain the highest global standards of quality and compliance. With a focus on maintaining excellence in quality, innovation, and competence, we continue to strengthen our capabilities and deliver sustainable value to all stakeholders.” Result PDF
Healthcare Services company Vimta Labs announced Q1FY26 results Total Income for Q1FY26 was at Rs 993 million. EBITDA for Q1FY26 was Rs 354 million; EBITDA margin was at 35.7%. PBT for Q1FY26 was at Rs 253 million. Q1FY26 PAT was at Rs 189 million; PAT margin was at 19.0% Basic EPS in Q1FY26 was Rs 4.2 Harita Vasireddi, Managing Director, Vimta Labs , said: “We are happy to report a revenue of Rs 993 million for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors. Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of cGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta's strong commitment to quality, and scientific rigor. As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company's strong financial position, confidence in future growth, and commitment to rewarding its shareholders. Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders.” Result PDF
Healthcare Services company Vimta Labs announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Income for Q4FY25 was at Rs 961 million. EBITDA for Q4FY25 was Rs 347 million; EBITDA margin was at 36.1%. PBT for Q4FY25 was at Rs 250 million. Q4FY25 PAT* was at Rs 183 million; PAT margin was at 19.1%. Basic EPS in Q4FY25 was Rs 8.2. FY25 Financial Highlights: Total Income for FY25 was at Rs 3,482 million. EBITDA for FY25 was Rs 1,262 million; EBITDA margin was at 36.2%. PBT for FY25 was at Rs 890 million. FY25 PAT* was at Rs 668 million; PAT margin was at 19.2%. Basic EPS in FY25 was Rs 30. Total Debt as of 31 st March 2025 stood at Rs 85 million. Cash and Cash equivalents including bank balance stood at Rs 329 million as of 31 st March 2025. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements. Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation. We are excited to announce our entry into Biologics Contract R&D; services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation. We remain committed to scaling our capabilities, driving innovation, and delivering long-term value for our stakeholders.” Result PDF
Healthcare Services company Vimta Labs announced 9MFY25 & Q3FY25 results Q3FY25 Financial Highlights: Total Income for Q3FY25 was at Rs 911 million. EBITDA for Q3FY25 was Rs 343 million; EBITDA margin was at 37.6%. PBT for Q3FY25 was at Rs 239 million. Q3FY25 PAT was at Rs 175 million; PAT margin was at 19.2%. Basic EPS in Q3FY25 was Rs 7.9. 9MFY25 Financial Highlights: Total Income for 9MFY25 was at Rs 2,521 million. EBITDA for 9MFY25 was Rs 915 million; EBITDA margin was at 36.3%. PBT for 9MFY25 was at Rs 640 million. 9MFY25 PAT was at Rs 484 million; PAT margin was at 19.2%. Basic EPS in 9MFY25 was Rs 21.8. Total Debt as of 31st December 2024 stood at Rs 113 million. Cash and Cash equivalents including bank balance stood at Rs 180 million as of 31st December 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are happy to report that Vimta Labs had another successful quarter with a strong growth of 21.1% YoY. This was mainly pushed by the Drug Development & Discovery Services. EBITDA margin for the quarter stood at 37.6% which is a growth of 496 bps on a YoY basis. During the quarter, our new addition to the Life Sciences Facility, was commercialised which has helped ease our operations giving us the space to work more efficiently. As we look to the future, we remain optimistic about our strategic direction and the robustness of our service offerings, which we believe will drive sustained growth and success.” Result PDF